GILEAD SCIENCES, INC. Total Contract Liability
GILEAD SCIENCES, INC. (GILD) had Total Contract Liability of $50.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability $50.00M.
- 2026-03-31: Contract with Customer, Liability $47.00M.
- 2025-12-31: Contract with Customer, Liability $48.00M.
- 2025-09-30: Contract with Customer, Liability $56.00M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2026-06-30 | $50.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $47.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $48.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $56.00M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $58.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $56.00M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $58.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $68.00M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $76.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $84.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $109.00M 10-K · filed 2025-02-28 |
| 2023-09-30 | $68.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $103.00M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $93.00M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $102.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | $85.00M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $98.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $117.00M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $79.00M 10-K · filed 2023-02-22 |
| 2021-09-30 | $85.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $87.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $91.00M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $97.00M 10-Q · filed 2021-11-03 |
| 2020-09-30 | $103.00M 10-Q · filed 2020-11-04 |
| 2019-12-31 | $45.00M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |